Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04019054 · ClinicalTrials.gov registry record · NA
TMS and Exposure Therapy
A NA study, sponsored by University of California, Los Angeles.
- Terminated
- Registry status
- NA
- Development phase
- 22
- Enrollment target
NCT04019054 is a NA study that was terminated before completion, run by University of California, Los Angeles. The registered enrollment target is 22 participants.
The verdict
NCT04019054, a NA study, was terminated before completion, sponsored by University of California, Los Angeles.
- TERMINATED
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
Study Summary
Spider phobia is an exceedingly common phobia throughout the world. The current standard treatment involves exposure therapy, which consists of a series of brief exposures of an individual to the thing they fear, in this case spiders. This study aims to examine the use of a neuromodulatory technology, transcranial magnetic stimulation (TMS), as a possible treatment option for spider phobia. TMS uses low-intensity electromagnetic energy to stimulate the brain, introducing energy into critical hubs of brain networks to "reset" their function and alleviate symptoms with very few side-effects. This study will consist of four separate visits. After screening subjects for spider phobia, baseline testing of subjective distress measures and physiologic stress data (heart rate variability and sweat response) during a prolonged spider exposure test will be collected. Subjects will then be placed into one of two groups: one receiving exposure therapy and intermittent Theta Burst Stimulation (iTBS) TMS (active study group), and another receiving exposure therapy with iTBS to a circuit not involved in a phobic reaction (control study group). Subjects will undergo their first treatment session during the first visit following the baseline data collection; the second and third treatments will occur the following two days. The fourth visit will occur one week after the third and consist of the same testing as the first visit; the same data will be collected. Changes from pre- to post-treatment in both subjective and physiologic data will be compared between the treatment and sham groups to examine effects of TMS on spider phobia.
Interventions
- DEVICE Intermittent Theta Burst Stimulation (iTBS), Ventromedial Prefrontal Cortex (vmPFC)
- DEVICE Intermittent Theta Burst Stimulation (iTBS), vertex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2019-08-19 |
| Est. Completion | 2020-03-18 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04019054
The ClinicalTrials.gov registry entry for NCT04019054 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Intermittent Theta Burst Stimulation (iTBS), Ventromedial Prefrontal Cortex (vmPFC) is the first listed.
NCT04019054 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04019054 about?
NCT04019054 is a clinical study titled "TMS and Exposure Therapy". Spider phobia is an exceedingly common phobia throughout the world. The current standard treatment involves exposure therapy, which consists of a series of brief exposures of an individual to the thing they fear, in this case spiders. This study aims to examine the use of a neuromodulatory technolog...
What is the current status of trial NCT04019054?
This trial is currently terminated. It is a NA study. The enrollment target is 22 participants. The study started on 2019-08-19. Estimated completion is 2020-03-18.
What interventions are being tested in trial NCT04019054?
The interventions under investigation include: Intermittent Theta Burst Stimulation (iTBS), Ventromedial Prefrontal Cortex (vmPFC) (DEVICE), Intermittent Theta Burst Stimulation (iTBS), vertex (DEVICE).
Who is sponsoring clinical trial NCT04019054?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.